Scienture Holdings, Inc. (SCNX) Fair Value & Analysis
Healthcare · US · Market cap $15.5M · ISIN US80880X1046
What is Scienture Holdings, Inc. really worth?
Scienture Holdings, Inc.
SCNX · US
Below-average quality, and trading another 32% above our fair value of $0.2805.
Risks
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 21 days ago
Share price −1.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.3506). The favourable scenario is already priced in.
- Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.2410 – $67.00 · fair‑value band $0.2104 – $0.3506 · the $0.3700 price screens above the $0.2805 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Scienture Holdings, Inc. (SCNX) currently trades at $0.3700, while our model-based Fair Value estimate is $0.2805, implying the stock looks roughly 31.9% overvalued today. The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of $0.3263 per share, and 0 of the 3 models we run sit above the $0.3700 price. Bear case: the DCF Models group reads lowest at $0.2129, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Trailing-twelve-month revenue stands at $478K. It earns a return on equity of −56.6%. The balance sheet holds a net cash position of $6.6M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.2104 (bear case) to $0.3506 (bull case); at $0.3700, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at −24%, SCNX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 3 models by family
Widest divergence: Multiples ($0.3263) versus Asset-Based ($0.0025). Highest evidence: Owner Earnings (78).
Notify me when SCNX reaches fair value
Put SCNX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 12
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
Full company description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Scienture Holdings, Inc. reported revenue of $432K in FY2025 versus $9.9M in FY2021, a compound −54.3%/yr. Reported net income was −$41.5M in FY2025.
SCNX screens 32% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 64 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.31 | ¥10.05 | −38% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
Compare Scienture Holdings, Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Scienture Holdings, Inc. (SCNX) overvalued or undervalued?
What is the fair value of SCNX?
What is the quality score of SCNX?
What is the revenue of Scienture Holdings, Inc. (SCNX)?
What is the net profit margin of SCNX?
Watch Scienture Holdings, Inc. in the live analysis
One click puts Scienture Holdings, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.